Effects of ectopic decorin in modulating intracranial glioma progression in vivo, in a rat syngeneic model

Cancer Gene Therapy

Volumn 11, Issue 11, 2004, Pages 721-732

  Biglari, Alireza ^a,b   Bataille, Dominique ^a,b   Naumann, Ulrike ^c   Weller, Michael ^c   Zirger, Jeffrey ^a   Castro, Maria G ^a,b,d   Lowenstein, Pedro R ^a,b,d  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

CNS 1 cells; Glioma; Recombinant adenovirus; Transfected glioma cells

Indexed keywords

DECORIN; GLIAL FIBRILLARY ACIDIC PROTEIN; PROTEOGLYCAN; TRANSFORMING GROWTH FACTOR BETA;

ADENOVIRUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; GENE TARGETING; GENE THERAPY; GENE TRANSFER; GRANULOMA; HUMAN CYTOMEGALOVIRUS; IMMUNOSUPPRESSIVE TREATMENT; INTRACRANIAL TUMOR; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BINDING; RAT; RAT STRAIN; TRANSGENE; TUMOR GROWTH; VIRUS RECOMBINANT;

ANIMALS; BASE SEQUENCE; BRAIN NEOPLASMS; CELL DIVISION; DISEASE MODELS, ANIMAL; DNA PRIMERS; EXTRACELLULAR MATRIX PROTEINS; GLIOMA; NEOPLASM TRANSPLANTATION; PROTEOGLYCANS; RATS; RATS, INBRED LEW; TRANSFECTION;

ADENOVIRIDAE; ANIMALIA; CUCUMBER MOSAIC VIRUS; CYTOMEGALOVIRUS; HUMAN HERPESVIRUS 5;

EID: 8444229365     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700783     Document Type: Article

References (46)

1. Iozzo RV. Matrix proteoglycans: from molecular design to cellular function. Annu Rev Biochem. 1998;67:609-652.
2. Kresse H, Schonherr E. Proteoglycans of the extracellular matrix and growth control. J Cell Physiol. 2001;189: 266-274.
3. Grant DS, Yenisey C, Rose RW, Tootell M, Santra M, Iozzo RV. Decorin suppresses tumor cell-mediated angiogenesis. Oncogene. 2002;21:4765-4777.
4. Yamaguchi Y, Ruoslahti E. Expression of human proteoglycan in Chinese hamster ovary cells inhibits cell proliferation. Nature. 1988;336:244-246.
5. Santra M, Skorski T, Calabretta B, Lattime EC, Iozzo RV. De novo decorin gene expression suppresses the malignant phenotype in human colon cancer cells. Proc Natl Acad Sci USA. 1995;92:7016-7020.
6. De Luca A, Santra M, Baldi A, Giordano A, Iozzo RV. Decorin-induced growth suppression is associated with upregulation of p21, an inhibitor of cyclin-dependent kinases. J Biol Chem. 1996;271:18961-18965.
7. Santra M, Mann DM, Mercer EW, Skorski T, Calabretta B, Iozzo RV. Ectopic expression of decorin protein core causes a generalized growth suppression in neoplastic cells of various histogenetic origin and requires endogenous p21, an inhibitor of cyclin-dependent kinases. J Clin Invest. 1997;100:149-157.
8. Moscatello DK, Santra M, Mann DM, McQuillan DJ, Wong AJ, Iozzo RV. Decorin suppresses tumor cell growth by activating the epidermal growth factor receptor. J Clin Invest. 1998;101:406-412.
9. Iozzo RV, Moscatello DK, McQuillan DJ, Eichstetter I. Decorin is a biological ligand for the epidermal growth factor receptor. J Biol Chem. 1999;274:4489-4492.
10. Csordas G, Santra M, Reed CC, et al. Sustained downregulation of the epidermal growth factor receptor by decorin. A mechanism for controlling tumor growth in vivo. J Biol Chem. 2000;275:32879-32887.
11. Reed CC, Gauldie J, Iozzo RV. Suppression of tumorigenicity by adenovirus-mediated gene transfer of decorin. Oncogene. 2002;21:3688-3695.
12. Santra M, Eichstetter I, Iozzo RV. An anti-oncogenic role for decorin. Down-regulation of ErbB2 leads to growth suppression and cytodifferentiation of mammary carcinoma cells. J Biol Chem. 2000;275:35153-35161.
13. Stander M, Naumann U, Dumitrescu L, et al. Decorin gene transfer-mediated suppression of TGF-beta synthesis abrogates experimental malignant glioma growth in vivo. Gene Therapy. 1998;5:1187-1194.
14. Kiefer R, Supler ML, Toyka KV, Streit WJ. In situ detection of transforming growth factor-beta mRNA in experimental rat glioma and reactive glial cells. Neurosci Lett. 1994; 166:161-164.
15. Sasaki A, Naganuma H, Satoh E. et al. Secretion of transforming growth factor-beta 1 and -beta 2 by malignant glioma cells. Neurol Med Chir (Tokyo). 1995;35:423-430.
16. Platten M, Wild-Bode C, Wick W, Leitlein J, Dichgans J, Weller M. N-[3,4-dimethoxycinnamoyl]-anthranilic acid (tranilast) inhibits transforming growth factor-beta relesase and reduces migration and invasiveness of human malignant glioma cells. Int J Cancer. 2001;93:53-61.
17. Dewey RA, Morrissey G, Cowsill CM, et al. Chronic brain inflammation and persistent herpes simplex virus 1 thymidine kinase expression in survivors of syngeneic glioma treated by adenovirus-mediated gene therapy: implications for clinical trials. Nat Med. 1999;5:1256-1263.
18. Cowsill C, Southgate TD, Morrissey G, et al. Central nervous system toxicity of two adenoviral vectors encoding variants of the herpes simplex virus type 1 thymidine kinase: reduced cytotoxicity of a truncated HSV1-TK. Gene Therapy. 2000;7:679-685.
19. Lowenstein PR. Immunology of viral-vector-mediated gene transfer into the brain: an evolutionary and developmental perspective. Trends Immunol. 2002;23:23-30.
20. Geddes BJ, Harding TC, Lightman SL, Uney JB. Long-term gene therapy in the CNS: reversal of hypothalamic diabetes insipidus in the Brattleboro rat by using an adenovirus expressing arginine vasopressin. Nat Med. 1997;3: 1402-1404.
21. Navarro V, Millecamps S, Geoffroy MC, et al. Efficient gene transfer and long-term expression in neurons using a recombinant adenovirus with a neuron-specific promoter. Gene Therapy. 1999;6:1884-1892.
22. Thomas CE, Schiedner G, Kochanek S, Castro MG, Lowenstein PR. Peripheral infection with adenovirus causes unexpected long-term brain inflammation in animals injected intracranially with first-generation, but not with high-capacity, adenovirus vectors: toward realistic long-term neurological gene therapy for chronic diseases. Proc Natl Acad Sci USA. 2000;97:7482-7487.
23. Thomas CE, Schiedner G, Kochanek S, Castro MG, Lowenstein PR. Preexisting antiadenoviral immunity is not a barrier to efficient and stable transduction of the brain, mediated by novel high-capacity adenovirus vectors. Hum Gene Ther. 2001;12:839-846.
24. Kruse CA, Molleston MC, Parks EP, Schiltz PM, Kleinschmidt-DeMasters BK, Hickey WF. A rat glioma model. CNS-1, with invasive characteristics similar to those of human gliomas: a comparison to 9L gliosarcoma. J Neurooncol. 1994;22:191-200.
25. Barth RF. Rat brain tumor models in experimental neurooncology: the 9L, C6, T9, F98, RG2 (D74), RT-2 and CNS-1 gliomas. J Neurooncol. 1998;36:91-102.
26. Karasuyama H, Kudo A, Melchers F. The proteins encoded by the VpreB and lambda 5 pre-B cell-specific genes can associate with each other and with mu heavy chain. J Exp Med. 1990;172:969-972.
27. Abe M, Harpel JG, Metz CN, Nunes I, Loskutoff DJ, Rifkin DB. An assay for transforming growth factor-beta using cells transfected with a plasminogen activator inhibitor-1 promoter-luciferase construct. Anal Biochem. 1994;216:276-284.
28. Trojan J, Johnson TR, Rudin SD, Ilan J, Tykocinski ML. Treatment and prevention of rat glioblastoma by immunogenic C6 cells expressing antisense insulin-like growth factor I RNA. Science. 1993;259:94-97.
29. Beutler AS, Banck MS, Aguzzi A. Curing rat glioblastoma: immunotherapy or graft rejection? Science. 1997;276:20-21.
30. Parsa AT, Chakrabarti I, Hurley PT, et al. Limitations of the C6/Wistar rat intracerebral glioma model: implications for evaluating immunotherapy. Neurosurgery. 2000;47: 993-999; discussion 999-1000.
31. Yamaguchi Y, Mann DM, Ruoslahti E. Negative regulation of transforming growth factor-beta by the proteoglycan decorin. Nature. 1990;346:281-284.
32. Border WA, Noble NA, Yamamoto T, et al. Natural inhibitor of transforming growth factor-beta protects against scarring in experimental kidney disease. Nature. 1992;360:361-364.
33. Isaka Y, Brees DK, Ikegaya K, et al. Gene therapy by skeletal muscle expression of decorin prevents fibrotic disease in rat kidney. Nat Med. 1996;2:418-423.
34. Takeuchi Y, Kodama Y, Matsumoto T. Bone matrix decorin binds transforming growth factor-beta and enhances its bioactivity. J Biol Chem. 1994;269:32634-32638.
35. Morelli AE, Larregina AT, Smith-Arica J, et al. Neuronal and glial cell type-specific promoters within adenovirus recombinants restrict the expression of the apoptosis-inducing molecule Fas ligand to predetermined brain cell types, and abolish peripheral liver toxicity. J Gen Virol. 1999;80(Part 3):571-583.
36. Smith-Arica JR, Morelli AE, Larregina AT, et al. Cell-type-specific and regulatable transgenesis in the adult brain: adenovirus-encoded combined transcriptional targeting and inducible transgene expression. Mol Ther. 2000;2:579-587.
37. Munz C, Naumann U, Grimmel C, Rammensee HG, Weller M. TGF-beta-independent induction of immunogenicity by decorin gene transfer in human malignant glioma cells. Eur J Immunol. 1999;29:1032-1040.
38. Tralhao JG, Schaefer L, Micegova M, et al. In vivo selective and distant killing of cancer cells using adenovirus-mediated decorin gene transfer. FASEB J. 2003;17:464-466.
39. Gerdes CA, Castro MG, Lowenstein PR. Strong promoters are the key to highly efficient, noninflammatory and noncytotoxic adenoviral-mediated transgene delivery into the brain in vivo. Mol Ther. 2000;2:330-338.
40. Shering AF, Bain D, Stewart K. Cell type-specific expression in brain cell cultures from a short human cytomegalovirus major immediate early promoter depends on whether it is inserted into herpesvirus or adenovirus vectors. J Gen Virol. 1997;78(Part 2):445-459.
41. Lowenstein PR, Shering AF, Bain D, Castro MG, Wilkinson GWG. The use of adenovirus vectors to transfer genes to identified target brain cells in vitro. In: P.R.a.E. Lowenstein LW, eds. Protocols for Gene Transfer in Neuroscience. Chichester: John Wiley and Sons; 1996: 93-114.
42. Southgate T, Kingston P, Castro MG. Gene transer into neural cells in vivo using adenoviral vectors. In: Gerfen CR, McKay R, Rogawski MA, Sibley DR, Skolnick P, eds. Current Protocols in Neuroscience. New York, NY: John Wiley and Sons; 2000: 4.23.1-4.23.40.
43. Dion LD, Fang J, Garver Jr RI. Supernatant rescue assay vs. polymerase chain reaction for detection of wild type adenovirus-contaminating recombinant adenovirus stocks. J Virol Methods. 1996;56:99-107.
44. Cotten M, Baker A, Saltik M, Wagner E, Buschle M. Lipopolysaccharide is a frequent contaminant of plasmid DNA preparations and can be toxic to primary human cells in the presence of adenovirus. Gene Therapy. 1994;1: 239-246.
45. Thomas CE, Abordo-Adesida E, Maleniak TC, Stone D, Gerdes G, Lowenstein PR. Gene transfer into rat brain using adenoviral vectors. In: Gerfen JN, McKay R, Rogawski MA, Sibley DR, Skolnick P, eds. Current Protocols in Neuroscience. New York, NY, John Wiley and Sons; 2000: 4.23.1-4.23.40.
46. Stone D, Xiong W, Williams JC, David A, Lowenstein PR, Castro MG. Adenovirus expression of IL-1 and NF-kappaB inhibitors does not inhibit acute adenoviral-induced brain inflammation, but delays immune system-mediated elimination of transgene expression. Mol Ther. 2003;8:400-411.